Combined estrogen plus progestin not tied to increased diabetes risk in postmenopausal women
In a recent study, researchers have said that compounded HT and estrogen alone for managing menopause symptoms increases type 2 diabetes risk. However, Combined estrogen plus progestin from the manufacturer has no association with the risk of diabetes.
It is already known that MHT or Menopausal hormone therapy reduce the incidence of type 2 diabetes mellitus (T2DM). There are changes in the types and dosages of female hormones used for MHT after the Women's Health Initiative study.
In the present research, researchers determined whether MHT is associated with an increased risk of T2DM in a retrospective cohort study that included the MHT group as postmenopausal women older than 40.
This study was based on national health insurance data and cancer screening data. MHT group had five categories; tibolone, combined estrogen plus progestin by the manufacturer (CEPM), oral estrogen, combined estrogen plus progestin by the physician (CEPP), and transdermal estrogen.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.